Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 6, 2012, Pages 867-881

  Bergsma, Hendrik ^a   Van Vliet, Esther I ^a   Teunissen, Jaap J M ^a   Kam, Boen L R ^a   De Herder, Wouter W ^a   Peeters, Robin P ^a   Krenning, Eric P ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Lutetium; Neuroendocrine tumours; Peptide receptor radionuclide therapy; PRRT; Somatostatin analogues; Yttrium

Indexed keywords

CAPECITABINE; CHELATING AGENT; CISPLATIN; DOTALAN Y 90; DOTATATE IN 111; DOTATATE LY 177; DOTATATE Y 90; DOTATOC IN 111; DOTATOC Y 90; FLUOROURACIL; LUTETIUM 177; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; TETRAXETAN; UNCLASSIFIED DRUG; YTTRIUM 90;

ADJUVANT THERAPY; ALPHA RADIATION; ARTICLE; BETA RADIATION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; GAMMA RADIATION; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROPANCREATIC NEUROENDOCRINE TUMOR; GATROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HALF LIFE TIME; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREATIC NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PROGRESSION FREE SURVIVAL; RADIATION; RADIATION DOSE; RADIOISOTOPE THERAPY; RENAL PROTECTION; SCINTIGRAPHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84876125539     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.01.004     Document Type: Review

References (62)

1. R. Arnold, R. Benning, C. Neuhaus, M. Rolwage, and M.E. Trautmann Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group Digestion 54 Suppl. 1 1993 72 75
2. E.T. Janson, and K. Oberg Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon Acta Oncol 32 1993 225 229
3. M. Ducreux, P. Ruszniewski, J.A. Chayvialle, J. Blumberg, D. Cloarec, and H. Michel The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors Am J Gastroenterol 95 2000 3276 3281
4. A. Rinke, H.-H. Müller, C. Schade-Brittinger, K.-J. Klose, P. Barth, and M. Wied Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
5. J.C. Reubi, B. Waser, J.C. Schaer, and J.A. Laissue Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur J Nucl Med 28 2001 836 846
6. H.R. Balon, S.J. Goldsmith, B.A. Siegel, E.B. Silberstein, E.P. Krenning, and O. Lang Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide J Nucl Med 2001 1134 1138
7. M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, and C. Uprimny 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 2007 508 518
8. I. Kayani, J.B. Bomanji, A. Groves, G. Conway, S. Gacinovic, and T. Win Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG Cancer 112 2008 2447 2455
9. E.P. Krenning, P.P. Kooij, W.H. Bakker, W.A. Breeman, P.T. Postema, and D.J. Kwekkeboom Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history Ann N Y Acad Sci 733 1994 496 506
10. R. Valkema, M. de Jong, W.H. Bakker, WAp Breeman, PPm Kooij, and P.J. Lugtenburg Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience Semin Nucl Med 32 2002 110 122
11. L.B. Anthony, E.A. Woltering, G.D. Espenan, M.D. Cronin, T.J. Maloney, and K.E. McCarthy Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies Semin Nucl Med 32 2002 123 132
12. J.C. Reubi, J.C. Schär, B. Waser, S. Wenger, A. Heppeler, and J.S. Schmitt Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 2000 273 282
13. S. Walrand, R. Barone, S. Pauwels, and F. Jamar Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts Eur J Nucl Med Mol Imaging 38 2011 1270 1280
14. J.A. O'Donoghue, M. Bardiès, and T.E. Wheldon Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides J Nucl Med 36 1995 1902 1909
15. M. de Jong, WAp Breeman, R. Valkema, B.F. Bernard, and E.P. Krenning Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs J Nucl Med 46 Suppl. 1 2005 13S 17S
16. A. Otte, E. Jermann, M. Behe, M. Goetze, H.C. Bucher, and H.W. Roser DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy Eur J Nucl Med 24 1997 792 795
17. A. Otte, R. Herrmann, A. Heppeler, M. Behe, E. Jermann, and P. Powell Yttrium-90 DOTATOC: first clinical results Eur J Nucl Med 26 1999 1439 1447
18. C. Waldherr, M. Pless, H.R. Maecke, A. Haldemann, and J. Mueller-Brand The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study Ann Oncol 12 2001 941 945
19. R. Valkema, S. Pauwels, L.K. Kvols, R. Barone, F. Jamar, and W.H. Bakker Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors Semin Nucl Med 36 2006 147 156
20. D.L. Bushnell, T.M. O'Dorisio, M.S. O'Dorisio, Y. Menda, R.J. Hicks, and E. Van Cutsem 90Y-edotreotide for metastatic carcinoid refractory to octreotide J Clin Oncol 28 2010 1652 1659
21. I. Virgolini, K. Britton, J. Buscombe, R. Moncayo, G. Paganelli, and P. Riva In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial Semin Nucl Med 32 2002 148 155
22. A.K. Pfeifer, T. Gregersen, H. Grønbæk, C.P. Hansen, J. Müller-Brand, and K. Herskind Bruun Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland Neuroendocrinology 93 2011 189 196
23. J.B. Cwikla, A. Sankowski, N. Seklecka, J.R. Buscombe, A. Nasierowska-Guttmejer, and K.G. Jeziorski Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study Ann Oncol 21 2010 787 794
24. A. Imhof, P. Brunner, N. Marincek, M. Briel, C. Schindler, and H. Rasch Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers J Clin Oncol 29 2011 2416 2423
25. C. Waldherr, M. Pless, H.R. Maecke, T. Schumacher, A. Crazzolara, and E.U. Nitzsche Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC J Nucl Med 43 2002 610 616
26. M. de Jong, R. Valkema, F. Jamar, L.K. Kvols, D.J. Kwekkeboom, and WAp Breeman Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings Semin Nucl Med 32 2002 133 140
27. F. Forrer, H. Uusijärvi, C. Waldherr, M. Cremonesi, P. Bernhardt, and J. Mueller-Brand A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 31 2004 1257 1262
28. J.P. Esser, E.P. Krenning, J.J.M. Teunissen, P.P.M. Kooij, A.L.H. van Gameren, and W.H. Bakker Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 33 2006 1346 1351
29. D.J. Kwekkeboom, W.H. Bakker, B.L. Kam, J.J.M. Teunissen, P.P.M. Kooij, and W.W. de Herder Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate Eur J Nucl Med Mol Imaging 30 2003 417 422
30. J.J.M. Teunissen, D.J. Kwekkeboom, and E.P. Krenning Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate J Clin Oncol 22 2004 2724 2729
31. S. Khan, E.P. Krenning, M. van Essen, B.L. Kam, J.J. Teunissen, and D.J. Kwekkeboom Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]Octreotate J Nucl Med 52 2011 1361 1368
32. D.J. Kwekkeboom, W.W. de Herder, B.L. Kam, C.H. van Eijck, M. van Essen, and P.P. Kooij Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2008 2124 2130
33. 177Lu-DOTATATE: the IEO phase I-II study Eur J Nucl Med Mol Imaging 38 2011 2125 2135
34. R. Valkema, S.A. Pauwels, L.K. Kvols, D.J. Kwekkeboom, F. Jamar, and M. de Jong Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate J Nucl Med 46 Suppl. 1 2005 83S 91S
35. M.C. Smith, J. Liu, T. Chen, H. Schran, C.M. Yeh, and F. Jamar OctreoTher: ongoing early clinical development of a somatostatin-receptor- targeted radionuclide antineoplastic therapy Digestion 62 Suppl. 1 2000 69 72
36. F. Forrer, H. Uusijärvi, D. Storch, H.R. Maecke, and J. Mueller-Brand Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC J Nucl Med 46 2005 1310 1316
37. L. Bodei, M. Cremonesi, M. Ferrari, M. Pacifici, C.M. Grana, and M. Bartolomei Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors Eur J Nucl Med Mol Imaging 35 2008 1847 1856
38. B. de Keizer, M.O. van Aken, R.A. Feelders, W.W. de Herder, B.L.R. Kam, and M. van Essen Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate Eur J Nucl Med Mol Imaging 35 2008 749 755
39. M. van Essen, E.P. Krenning, B.L.R. Kam, W.W. de Herder, R.A. Feelders, and D.J. Kwekkeboom Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors J Nucl Med 51 2010 383 390
40. C. Swärd, P. Bernhardt, H. Ahlman, B. Wängberg, E. Forssell-Aronsson, and M. Larsson [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney World J Surg 34 2010 1368 1372
41. M. de Jong, and T. Maina Of mice and humans: are they the same?-Implications in cancer translational research J Nucl Med 51 2010 501 504
42. A. Frilling, F. Weber, F. Saner, A. Bockisch, M. Hofmann, and J. Mueller-Brand Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors Surgery 140 2006 968 977
43. L. Villard, A. Romer, N. Marincek, P. Brunner, M.T. Koller, and C. Schindler Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers J Clin Oncol 30 2012 1100 1106
44. J. Kunikowska, L. Królicki, A. Hubalewska-Dydejczyk, R. Mikołajczak, A. Sowa-Staszczak, and D. Pawlak Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38 2011 1788 1797
45. E. Seregni, M. Maccauro, A. Coliva, M.R. Castellani, E. Bajetta, and G. Aliberti Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results Q J Nucl Med Mol Imaging 54 2010 84 91
46. D.J. Kwekkeboom Therapy: neuroendocrine cancer-are two radionuclides better than one? Nat Rev Endocrinol 2012 Jul 326 328
47. D. Kaemmerer, V. Prasad, W. Daffner, D. Hörsch, G. Klöppel, and M. Hommann Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor World J Gastroenterol 15 2009 5867 5870
48. A. Sowa-Staszczak, D. Pach, and R. Chrzan Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs) Eur J Nucl Med Mol Imaging 38 2011 1669 1674
49. T.W. Barber, M.S. Hofman, B.N.J. Thomson, and R.J. Hicks The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable Eur J Surg Oncol 38 2012 64 71
50. M.K.G. McStay, D. Maudgil, M. Williams, J.M. Tibballs, A.F. Watkinson, and M.E. Caplin Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy Radiology 237 2005 718 726
51. C. Kratochwil, R. López-Benítez, W. Mier, S. Haufe, B. Isermann, and H.-U. Kauczor Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases Endocr Relat Cancer 18 2011 595 602
52. G.S. Limouris, A. Chatziioannou, D. Kontogeorgakos, D. Mourikis, M. Lyra, and P. Dimitriou Selective hepatic arterial infusion of In-111-DTPA-Phe1- octreotide in neuroendocrine liver metastases Eur J Nucl Med Mol Imaging 35 2008 1827 1837
53. N.N. Sawada, T.T. Ishikawa, F.F. Sekiguchi, Y.Y. Tanaka, and H.H. Ishitsuka X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
54. T.A. Rich, R.C. Shepard, and S.T. Mosley Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy J Clin Oncol 22 2004 2214 2232
55. M. van Essen, E.P. Krenning, B.L. Kam, W.W. de Herder, M.O. van Aken, and D.J. Kwekkeboom Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 35 2008 743 748
56. P.G. Claringbold, P.A. Brayshaw, R.A. Price, and J.H. Turner Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours Eur J Nucl Med Mol Imaging 38 2011 302 311
57. J.G. Jurcic, S.M. Larson, G. Sgouros, M.R. McDevitt, R.D. Finn, and C.R. Divgi Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 2002 1233 1239
58. S. Nilsson, L. Franzén, C. Parker, C. Tyrrell, R. Blom, and J. Tennvall Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594
59. M.R. Zalutsky, D.A. Reardon, G. Akabani, R.E. Coleman, A.H. Friedman, and H.S. Friedman Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 J Nucl Med 49 2008 30 38
60. T. Nayak, J. Norenberg, T. Anderson, and R. Atcher A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro Cancer Biother Radiopharm 20 2005 52 57
61. T.K. Nayak, J.P. Norenberg, T.L. Anderson, E.R. Prossnitz, M.G. Stabin, and R.W. Atcher Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells Nucl Med Biol 34 2007 185 193
62. C. Kratochwil, F.L. Giesel, A. Morgenstern, F. Bruchertseifer, W. Mier, and C. Zechmann Regional 213Bi-DOTATOC peptide receptor alpha-therapy in patients with neuroendocrine liver metastases refractory to beta-radiation J Nucl Med 52 Suppl. 1 2011 29 (abstract)